|
| U.S. Brand
Names |
|
| Loprox® |

|
|
| Generic
Available |
|
|
No |

|
|
| Synonyms |
|
|
Ciclopirox Olamine |

|
|
| Pharmacological Index |
|
|
Antifungal Agent, Topical |

|
|
| Use |
|
|
Treatment of tinea pedis (athlete's foot), tinea cruris (jock itch), tinea
corporis (ringworm), cutaneous candidiasis, and tinea versicolor
(pityriasis) |

|
|
| Pregnancy Risk
Factor |
|
|
B |

|
|
| Contraindications |
|
|
Known hypersensitivity to ciclopirox or any of its components; avoid
occlusive wrappings or dressings |

|
|
| Warnings/Precautions |
|
|
For external use only; avoid contact with eyes |

|
|
| Adverse
Reactions |
|
|
1% to 10%:
Local: Irritation, redness, burning, or pain |

|
|
| Drug
Interactions |
|
|
No data reported |

|
|
| Mechanism of
Action |
|
|
Inhibiting transport of essential elements in the fungal cell causing
problems in synthesis of DNA, RNA, and protein |

|
|
| Pharmacodynamics/Kinetics |
|
|
Absorption: <2% absorbed through intact skin
Distribution: To epidermis, corium (dermis), including hair, hair follicles,
and sebaceous glands
Protein binding: 94% to 98%
Half-life: 1.7 hours
Elimination: Of the small amounts of systemically absorbed drug, majority
excreted by the kidney with small amounts excreted in feces
|

|
|
| Usual Dosage |
|
|
Children >10 years and Adults: Apply twice daily, gently massage into
affected areas; if no improvement after 4 weeks of treatment, re-evaluate the
diagnosis |

|
|
| Mental Health: Effects
on Mental Status |
|
|
None reported |

|
|
| Mental Health:
Effects on Psychiatric
Treatment |
|
|
None reported |

|
|
| Dental Health: Local
Anesthetic/Vasoconstrictor
Precautions |
|
|
No information available to require special precautions |

|
|
| Dental Health:
Effects on Dental Treatment |
|
|
No effects or complications reported |

|
|
| Patient
Information |
|
|
Avoid contact with eyes; if sensitivity or irritation occurs, discontinue
use |

|
|
| Nursing
Implications |
|
|
Avoid contact with eyes; if sensitivity or irritation occurs, discontinue
use |

|
|
| Dosage Forms |
|
|
Cream, topical, as olamine: 1% (15 g, 30 g, 90 g)
Lacquer, nail, topical solution: 8% (3.3 mL)
Lotion, as olamine: 1% (30 mL, 60 mL)
|

|
|
Copyright © 2007 Drugs Area
|